CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DKITV559DPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib Anhydrous,Imatinib,PonatinibGarner et al., 2014
CPIK3CAE81KPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,Fluorouracil,OxaliplatinDe Roock et al., 2010
CPIK3CAR93WPredictiveSupportsResistanceColorectal CancerFluorouracil,Oxaliplatin,CetuximabDe Roock et al., 2010
DBCR::ABL1Fusion AND ABL1 F311IPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
CBCR::ABL1Fusion AND ABL1 F311IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F359CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 E453QPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
DAKT1Q79KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DBCR::ABL1Fusion AND ABL1 L384MPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 F359IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
CBCR::ABL1Fusion AND ABL1 F359IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F359IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
DBCR::ABL1Fusion AND ABL1 M343TPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 F317VPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
CBCR::ABL1Fusion AND ABL1 F311LPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 H396PPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
DBCR::ABL1Fusion AND ABL1 G398RPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 E450VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
DKITK550_W557delPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib Anhydrous,Ponatinib,Imatinib,SunitinibGarner et al., 2014
CKITD820YPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousGeorge et al., 2012
CKITN822KPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousGeorge et al., 2012
BKITExon 11 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousDemetri et al., 2013
CEML4::ALKFusion AND ALK G1269APredictiveSupportsResistanceLung AdenocarcinomaCrizotinibSaber et al., 2016
DBRCA1W1815XPredictiveSupportsSensitivity/ResponseEndometrioid Ovary CarcinomaOlaparibStordal et al., 2013
BKITExon 9 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousDemetri et al., 2013
BKITExon 11 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousGeorge et al., 2012
BEGFRRare Exon 18-21 MutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibWu et al., 2011
CPOLD1E374KPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPembrolizumabRizvi et al., 2015
DPIK3CAD350GPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DKITS628NPredictiveSupportsSensitivity/ResponseCancerDasatinib,ImatinibVita et al., 2014
BESR1D538GPredictiveDoes Not SupportSensitivity/ResponseBreast CancerPalbociclib,LetrozolePMID 27556863
DARID1AP1175FS*5PredictiveSupportsSensitivity/ResponseOvarian Clear Cell CarcinomaDasatinibMiller et al., 2016
BCD274ExpressionPrognosticSupportsPoor OutcomeBreast CancerWang et al., 2017
BCD274ExpressionPrognosticSupportsBetter OutcomeCancerZhao et al., 2017
EKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaImmune Checkpoint InhibitorLi et al., 2017
CVHLH115Q (c.345C>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLF119L (c.357C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLA149T (c.445G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLN78T (c.233A>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLP86A (c.256C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLW88R (c.262T>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLS111N (c.332G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLC162R (c.484T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLC162F (c.485G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLC162W (c.486C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLL184P (c.551T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLE186K (c.556G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLA56fs (c.166_167insA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLL101G (c.301_302delinsGG)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
Page 78 of 96
PreviousNext